tbuckley/cabot-search huggingface dataset:
Retrovirus-mediated gene transfer of human pyruvate kinase (PK) cDNA into murine hematopoietic cells: implications for gene therapy of human PK deficiency
Authors: K Tani, T Yoshikubo, K Ikebuchi, K Takahashi, T Tsuchiya, S Takahashi, M Shimane, H Ogura, A Tojo, K Ozawa
Journal: Blood (1994)
Visualization of Parathyroid Hyperplasia Using 18F-Fluorocholine PET/MR in a Patient With Secondary Hyperparathyroidism
Authors: Martin W. Huellner, Susanne Aberle, Bert-Ram Sah, Patrick Veit-Haibach, Marco Bonani, Christoph Schmid, Hans Steinert
Journal: Clinical Nuclear Medicine (2015)

Several imaging modalities exist for the detection of parathyroid adenomas in patients with primary hyperparathyroidism. Unlike solitary parathyroid adenoma, parathyroid hyperplasia in patients with secondary hyperparathyroidism hitherto is difficult to assess with any imaging modality. Our case of a young patient with chronic kidney failure illustrates that F-fluorocholine PET/MR might be an imaging tool suitable for the diagnosis and presurgical assessment of parathyroid hyperplasia.
Carboplatin Monochemotherapy in Elderly Patients with Nonoperable Transitional Cell Carcinoma of the Bladder: A Two-Stage, Phase II Study
Authors: R. Segati, M. Bari, G. Azzarello, C. Signorelli, M. Marchini, G. Fiaccavento, M. Longo, G.L. Pappagallo, O. Vinante
Journal: European Urology (1996)
Organic brain syndrome associated with marginal hypothyroidism
Authors: J J Haggerty, D L Evans, A J Prange
Journal: American Journal of Psychiatry (1986)

The authors report organic brain dysfunction in two psychiatric patients with grade 2 hypothyroidism; one was depressed and one had a paranoid psychosis with depressive features. The depression and psychosis responded to psychotropic medication and L-thyroxine, but the cognitive dysfunction improved only partially.
AB0792 Changes in the Metabolism of Hyaluronan Are Associated with Inflammatory Cytokines in Patients with Ankylosing Spondylitis
Authors: U. Hellman, D. Hedqvist, L. Do, B. Sundström, S. Wållberg-Jonsson
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Hyaluronan (HA) is a glucosaminoglycane, mainly known for its lubricating and shock absorbing properties in joints, present in almost every tissue in the body. An association was recently reported between the concentration of HA and back stiffness in patients with ankylosing spondylitis (AS). Depending on the molecular size, HA also has different inflammatory properties. <h3>Objectives</h3> The aim of this study was to analyze plasma levels of HA in patients with AS and a reference population to evaluate any difference between the groups regarding HA concentration and/or molecular weight of HA molecules. In the AS group, these results were related with variables reflecting inflammation and stiffness. <h3>Methods</h3> In a cohort of 66 patients (51 males, 15 females, mean age 47.7 years) with AS and a matched reference population of 30 controls, HA concentration was determined using enzyme-linked immunosorbent assay (ELISA). Subgroups comprising in all 30 patients and eleven controls were selected with respect to inflammatory status and stiffness. These subgroups were analysed for HA molecular weight using gas-phase electrophoretic molecular mobility analysis (GEMMA). In the patient group, the HA results were related to inflammatory variables (ESR, hsCRP, ASDAS, cytokines), functional disease activity (BASDAI) and back stiffnes according to a BASFI, question 8 (“looking over the shoulder without turning the body”). <h3>Results</h3> No difference was found between the groups regarding HA total concentration (p=0.77). However, when assessing the molecular weight with GEMMA, a relative increase of high molecular weight (HMW) HA was found compared to low molecular weight (LMW) HA. HMW HA (GEMMA peak 4) increased with a fold change of 2.4 (p&lt;0.02). The levels of a group of cytokines, TNF-α, IL-6, IL-17 and IFN-γ, were well correlated in the AS patients (p&lt;0.05-0.0001). The levels of TNF-α and IL-6 also correlated with the relative increase of HMW HA (peak 4), compared to LMW HA. No significant correlations could be found between HA and the functional or stiffness status of the patients. <h3>Conclusions</h3> The correlation of the levels of inflammatory markers with changes in the HA metabolism may indicate an association of HA with the disease process in AS. Furthermore, HA showed a link to inflammatory processes via TNF. The significant correlation found among the patients between the concentrations of HA of a certain molecular weight and TNF-α is challenging, since TNF-α inhibitors are used successfully in the treatment of AS. However, the patients9 estimation of their stiffness could not be related to the molecular analyses. <h3>Disclosure of Interest</h3> None declared
Aortic Stenosis
Authors: Blase A Carabello
Journal: New England Journal of Medicine (2002)

A 60-year-old man is evaluated for a heart murmur. He jogs regularly and has no cardiac symptoms. Examination reveals a delayed carotid upstroke and a grade 3/6 late-peaking systolic ejection murmur. Echocardiography shows normal systolic function and a heavily calcified aortic valve, with a peak Doppler transvalvular gradient of 64 mm Hg and a calculated valve area of 0.7 cm2.
What Need for Speed?
Authors: E.J. H.
Journal: Annals of Internal Medicine (1971)

Editorials1 April 1971What Need for Speed?E.J. H.E.J. H.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-74-4-629 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOn January 6 the House Select Committee on Crime recommended to Congress new legislation for the control of crime (1). Along with other measures, it asked for legal restrictions on manufacture and distribution of the amphetamines. Among the witnesses who had testified before the Committee during the prereport deliberations (2) and provided support for the Committee's recommendations was Dr. George Edison, Director, Student Health Service, University of Utah. He was not alone in his views. Other authorities also called attention to misuses of the amphetamines by the public and by physicians and asked for legal controls on the amphetamines. Dr....References1. House unit backs pretrial jailing of drug pushers. The New York Times 7 January 1971, p. 1 Google Scholar2. Crime in America—Why 8 Billion Amphetamines? Hearings Before the Select Committee on Crime, House of Representatives, Ninety-First Congress, First Session, Pursuant to H. Res. 17, A Resolution Creating a Select Committee to Conduct Studies and Investigations of Crime in the United States, November 18, 1969, Washington, D.C. Washington D.C., U.S. Government Printing Office, 1970 Google Scholar3. Ibid., p. 6 Google Scholar4. Ibid., p. 15 Google Scholar5. Ibid., pp. 20, 21 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1971Volume 74, Issue 4Page: 629-630KeywordsAmphetaminesCrimeLegislationMedical services Issue Published: 1 April 1971 PDF downloadLoading ...
Effect of Intravenous Glucose on Gastric Lactic Acid in Gastric Carcinoma&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Authors: Shacter, Bernard, Byron, Ralph L., Shimkin, Michael B.
Journal: JNCI Journal of the National Cancer Institute (1949)

Journal Article Effect of Intravenous Glucose on Gastric Lactic Acid in Gastric Carcinoma Get access Bernard Shacter, Bernard Shacter Search for other works by this author on: Oxford Academic PubMed Google Scholar Ralph L. Byron, Jr., Ralph L. Byron, Jr. Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael B. Shimkin Michael B. Shimkin Laboratory of Experimental Oncology National Cancer Institute, National Institutes of Health, Public Health Service, and the University of California Medical School, San Francisco Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 2, October 1949, Pages 331–336, https://doi.org/10.1093/jnci/10.2.331 Published: 01 October 1949
OP0148 The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts
Authors: A. Tubery, C. Castelli, F. Erny, F. Barchechath-Flaisler, S. Dadoun, B. Fautrel, C. Gaujoux Viala
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The addition of biological agents in chronic inflammatory arthritides (CIAs) therapeutic strategies has improved the possibility of controlling disease activity and slowing the progression of joint damage. However their impact on work participation remains unclear. <h3>Objectives</h3> To assess the effect of biological agents on work among patients with chronic inflammatory arthritides. <h3>Methods</h3> A systematic review of the literature using Pubmed-Medline and the Cochrane library was performed until January 2014. All randomized controlled trials (RCTs) and controlled cohorts (CCs) reporting the effect of biological agents on work among patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis (PsA) were selected. Data extraction: Data were collected using a predetermined form. The outcomes were accumulated missed workdays, number of patients losing worktime due to CIAs, impact on productivity (on a visual analogue scale) and employment loss. Statistical analysis determined in each study effect size (ES) or odds-ratios (OR) as appropriate to assess the magnitude of treatment effect. Pooled ES and OR were computed by meta-analysis. A random effect model was used in case of heterogeneity. <h3>Results</h3> 15 RCTs and 7 CCs were analyzed i.e. 15881 patients treated by biological agents (adalimumab, etanercept, infliximab, certolizumab, golimumab and abatacept) and 9713 controls. Among those 25594 patients, 24670 suffered from RA, 319 from AS, and 605 from PsA. Pooled analyses indicated that biological agents significantly reduced accumulated missed workdays at week 24 (2 trials): SRM= -0.34 [95%CI -0.60 to -0.08], the number of patients losing hours (3 trials): OR=0.54 [95%CI 0.36 to 0.79] and improved work productivity (3 trials): ES=-1.58 [95%CI -2.66 to -0.51]. The positive effect on employment loss was nearly significant (8 trials): OR=0.60 [95% CI 0.33 to 1.09]. <h3>Conclusions</h3> Despite the heterogeneity of the data, this meta-analysis showed the beneficial effect of biologics agents on both absenteeism and presenteeism in chronic inflammatory rheumatism. Thus the high cost of biologic agents could be partly balanced with savings in indirect costs. <h3>Disclosure of Interest</h3> A. Tubery: None declared, C. Castelli: None declared, F. Erny Speakers bureau: Abbvie; Amgen, F. Barchechath-Flaisler Speakers bureau: Abbvie; Amgen, S. Dadoun: None declared, B. Fautrel Speakers bureau: Abbvie, BMS, MSD, Nordic-Pharma, Pfizer, Roche-Chugai, UCB, C. Gaujoux Viala Consultant for: Abbvie, BMS, Janssen Pharmaceutica Product LP, MSD, Nordic-Pharma, Pfizer Inc, UCB, Roche Pharmaceuticals
High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Carla L. Alves, Daniel Elias, Maria Lyng, Martin Bak, Tove Kirkegaard, Anne E. Lykkesfeldt, Henrik J. Ditzel
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Resistance to endocrine therapy in estrogen receptor–positive (ER+) breast cancer remains a major clinical problem. Recently, the CDK4/6 inhibitor palbociclib combined with letrozole or fulvestrant was approved for treatment of ER+ advanced breast cancer. However, the role of CDK4/6 in endocrine resistance and their potential as predictive biomarkers of endocrine treatment response remains undefined. Experimental Design: We investigated the specific role of increased CDK6 expression in fulvestrant-resistant cells by gene knockdown and treatment with palbociclib, and evaluated the effect in cell proliferation, apoptosis, and kinase activity. Furthermore, we evaluated CDK6 expression in metastatic samples from breast cancer patients treated or not with fulvestrant. Results: We found increased expression of CDK6 in two fulvestrant-resistant cell models versus sensitive cells. Reduction of CDK6 expression impaired fulvestrant-resistant cell growth and induced apoptosis. Treatment with palbociclib resensitized fulvestrant-resistant cells to fulvestrant through alteration of retinoblastoma protein phosphorylation. High CDK6 levels in metastatic samples from two independent cohorts of breast cancer patients treated with fulvestrant (N = 45 and 46) correlated significantly with shorter progression-free survival (PFS) on fulvestrant treatment (P = 0.0006 and 0.018), whereas no association was observed in patients receiving other first- or second-/third-line endocrine treatments (N = 68, P = 0.135 and 0.511, respectively). Conclusions: Our results indicate that upregulation of CDK6 may be an important mechanism in overcoming fulvestrant-mediated growth inhibition in breast cancer cells. Patients with advanced ER+ breast cancer exhibiting high CDK6 expression in the metastatic lesions show shorter PFS upon fulvestrant treatment and thus may benefit from the addition of CDK4/6 inhibitors in their therapeutic regimens. Clin Cancer Res; 22(22); 5514–26. ©2016 AACR.
Diagnosis in oncology. Mantle-cell lymphoma.
Authors: J Chen, S H Swerdlow, S A Jacobs
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.7.2568 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9667279 Diagnosis in oncology. Mantle-cell lymphoma. J ChenxJ ChenSearch for articles by this author , S H SwerdlowxS H SwerdlowSearch for articles by this author , S A JacobsxS A JacobsSearch for articles by this author Show More University of Pittsburgh Medical Center and UPMC Shadyside Hospital, PA, USA. https://doi.org/10.1200/JCO.1998.16.7.2568 PDF "Diagnosis in oncology. Mantle-cell lymphoma.." Journal of Clinical Oncology, 16(7), pp. 2568–2569© 1998 by American Society of Clinical Oncology
Studies on the Effect of Pyruvate on the Desamidation of Glutamine, Asparagine, and Related Compounds
Authors: Vincent E. Price, Jesse P. Greenstein
Journal: JNCI Journal of the National Cancer Institute (1947)

Studies on the Effect of Pyruvate on the Desamidation of Glutamine, Asparagine, and Related Compounds Get access Vincent E. Price, Vincent E. Price assistant surgeon National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Jesse P. Greenstein Jesse P. Greenstein principal biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 7, Issue 4, February 1947, Pages 275–279, https://doi.org/10.1093/jnci/7.4.275 Published: 01 February 1947 Article history Received: 02 January 1947 Published: 01 February 1947
Effect of a Normal Serum Protein Absent From Hepatoma-Bearing Animals on Cell Cultures 2
Authors: Mary L. Dolan, Mona L. Coetzee, Peter Ove
Journal: JNCI Journal of the National Cancer Institute (1975)

The effect of a serum factor purified from normal rat serum on growth and incorporation of 3H-thymidine and 3H-leucine was investigated with the use of 3T3 and L cells. The factor was not present in serum of hepatoma-bearing animals at a time when the weight of the hepatomas was equal to or greater than liver weight. The factor disappeared gradually from the serum of hepatoma-bearing animals, and the disappearance was proportional to the increase in the size of the hepatomas. Diminished amounts of the factor could be detected as early as 10 days after hepatoma transplant, and the factor was absent at 30 days after hepatoma transplant from the serum of rats bearing hepatoma 7777. Medium supplemented with 5% normal rat serum supported incorporation of label into 3T3 and L cells and growth of these cells, as did medium supplemented with 10% calf serum. Serum from hepatoma-bearing animals was only ≈50% as efficient as normal rat serum in supporting growth and label incorporation. The addition of purified factor to the serum from hepatoma-bearing animals restored the ability of the serum to support growth and label incorporation to between 70 and 90% of that found with normal rat serum as a medium supplement. The factor also enhanced incorporation of 3H-thymidine following release of 3T3 cells from contact inhibition.
Adverse Effects of Proton Pump Inhibitors in Chronic Kidney Disease
Authors: Ruben Poesen, Björn Meijers, Pieter Evenepoel
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
SP0108 MSC Based Therapy for Severe Osteoarthritis of the Knee: The Adipoa Experience
Authors: C. Jorgensen
Journal: Annals of the Rheumatic Diseases (2015)

Adipose derived mesenchymal stromal cells (ASC) are adult stem cells exhibiting functional properties that have open the way for cell-based clinical therapies. Primarily, their capacity of multilineage differentiation has been explored in a number of strategies for skeletal tissue regeneration. More recently, MSCs have been reported to exhibit immunosuppressive as well as healing capacities, to improve angiogenesis and prevent apoptosis or fibrosis through the secretion of paracrine mediators. Among the degenerative diseases associated with aging, osteoarthritis is the most common pathology and affects 16% of the female population over 65 years. Up to now, no therapeutic option exists to obtain a sustainable improvement of joint function beside knee arthroplasty. This prompted us to propose adipose derived stem cells as a possible cell therapy. We performed pre-clinical models of osteoarthritis, and showed that a local injection of ASC showed a reduction of synovitis, reduction of osteophytes, joint stabilization, reducing the score of cartilage lesions. This work was completed by toxicology data showing the excellent tolerance of the local injection of ADSC and biodistribution showing the persistence of cells after 6 months in murine models. In this open-label phase 1 trial we included 18 patients with severe osteoarthritis of the knee in failure of conventional therapies (62.5% were KL IV) at two sites, Montpellier and Wurzburg. Mean age was 61 years, with a 10 years history of knee OA. The patient received a single injection of autologous ASC 15 days after lipoaspiration (2.10<sup>6</sup>, 10<sup>7</sup> or 5.10<sup>7</sup>) through intra-articular injection. The primary outcome measure of effectiveness was patient-reported WOMAC pain subscores by VAS in the affected knee at week 12. Secondary outcome measures included Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT OARSI) responses. We observed a decrease of the VAS Pain (73±11 mm day 0 to 32±23 month 3), and of WOMAC (50±18 to 25±7 month 3). This study confirms the feasibility and safety of local injection of autologous cells from adipose tissue and suggested that the most effective dose was 10<sup>7</sup> autologous cells. The ADIPOA research teams performed successfully the phase 1 clinical trial is in France and Germany. A phase 2B controlled trial is scheduled to confirm the clinical benefit of this strategy. <h3>Disclosure of Interest</h3> None declared
Correlation between the dexamethasone suppression test in depressed patients and clinical response
Authors: C B Nemeroff, D L Evans
Journal: American Journal of Psychiatry (1984)

Eighteen psychiatric inpatients who fulfilled DSM-III criteria for major depression and who had a positive dexamethasone suppression test after admission were later retested. Of the 13 patients who exhibited cortisol suppression at discharge, two relapsed within 6 months; five remained nonsuppressors at discharge, and all either required further inpatient care or were symptomatic within 2 weeks to 4 months. Continued cortisol nonsuppression was thus associated with poor clinical response or high risk of relapse.
IMMUNE COMPLEX DISEASE IN CHRONIC VIRAL INFECTIONS
Authors: Michael B. A. Oldstone, Frank J. Dixon
Journal: The Journal of Experimental Medicine (1971)

Chronic viral infections of animals associated with immune complex disease resemble a number of human disorders. At present, on the basis of showing (a) virus, host antiviral antibody, and C3 deposited in a granular pattern along the glomerular capillary wall and in the mesangia and (b) virus-host Ig (presumably antiviral antibody) complexes in the circulation, immune complex disease occurs in chronic murine infections with LCM, LDV, MSV, and ADM. In addition, granular deposits in the glomeruli in Coxsachie B, polyoma, other leukemic viral infections in mice, equine anemia, and hog cholera suggest that immune complex disease also occurs in these infections. In transplacental LCM infections maternal antiviral antibody transferredin utero or via milk induces very early and severe immune complex disease. The severity of immune complex nephritis in mice neonatally or transplacentally infected with LCM virus is directly proportional to the amount of Ig elutable from the kidney and to the proportion of this Ig which reacts with the infecting virus.
Case 51-1973
Authors: Richard C. Cabot, Benjamin Castleman, Robert E. Scully, Betty U. McNeely, Cecil H. Coggins, Benjamin Castleman
Journal: New England Journal of Medicine (1973)

Presentation of CaseA 72-year-old woman was admitted to the hospital because of respiratory distress.She was well until 23 years previously, when hypertension was found. Twelve years before admission there was the onset of painful swellings in both lower extremities, and examination disclosed cyanotic, atrophic, cold areas of skin over the anterior aspect of the tibias, with tender swellings. A biopsy specimen from the leg was interpreted as consistent with periarteritis. Adrenal corticosteroid treatment was instituted, with improvement. Attempts to omit the medication were followed by recurrence of symptoms, and the treatment was continued. During the three years before . . .